Your browser is no longer supported. Please, upgrade your browser.
Settings
ACRX AcelRx Pharmaceuticals, Inc. daily Stock Chart
ACRX [NASD]
AcelRx Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own1.20% Shs Outstand44.36M Perf Week4.69%
Market Cap188.09M Forward P/E- EPS next Y-0.74 Insider Trans8.34% Shs Float43.50M Perf Month2.91%
Income-32.10M PEG- EPS next Q-0.24 Inst Own73.60% Short Float13.73% Perf Quarter16.80%
Sales7.20M P/S26.12 EPS this Y-30.50% Inst Trans-8.77% Short Ratio11.21 Perf Half Y-53.56%
Book/sh0.75 P/B5.65 EPS next Y-37.00% ROA-39.80% Target Price5.50 Perf Year-40.45%
Cash/sh1.15 P/C3.67 EPS next 5Y- ROE-71.00% 52W Range2.96 - 9.32 Perf YTD-37.00%
Dividend- P/FCF- EPS past 5Y5.80% ROI-52.70% 52W High-54.51% Beta2.03
Dividend %- Quick Ratio4.00 Sales past 5Y- Gross Margin- 52W Low43.24% ATR0.27
Employees50 Current Ratio4.00 Sales Q/Q2609.90% Oper. Margin- RSI (14)50.17 Volatility7.39% 6.41%
OptionableYes Debt/Eq0.69 EPS Q/Q16.70% Profit Margin- Rel Volume1.00 Prev Close4.24
ShortableYes LT Debt/Eq0.41 EarningsAug 03 AMC Payout- Avg Volume532.54K Price4.24
Recom2.40 SMA20-1.70% SMA500.70% SMA200-19.00% Volume0 Change0.00%
Jul-10-15Resumed ROTH Capital Buy $7.50
May-06-15Reiterated Mizuho Neutral $5.50 → $3
May-05-15Reiterated RBC Capital Mkts Outperform $8 → $7
Mar-10-15Reiterated RBC Capital Mkts Outperform $12 → $8
Mar-09-15Downgrade Mizuho Buy → Neutral $14 → $5.59
Feb-26-15Upgrade Mizuho Neutral → Buy $6 → $14
Nov-06-14Downgrade Mizuho Buy → Neutral $15 → $6
Sep-26-14Downgrade ROTH Capital Buy → Neutral
Jul-28-14Reiterated RBC Capital Mkts Outperform $15 → $12
Jul-28-14Reiterated Mizuho Buy $20 → $15
Jul-28-14Downgrade Canaccord Genuity Buy → Hold
Apr-17-14Initiated Canaccord Genuity Buy $16
Jan-07-14Initiated RBC Capital Mkts Outperform $15
Dec-19-13Reiterated Mizuho Buy $18 → $20
Dec-17-13Reiterated MLV & Co Buy $15 → $16.50
Jul-17-13Reiterated Mizuho Neutral $13 → $18
Feb-04-13Initiated MLV & Co Buy $13
Jan-30-13Initiated Mizuho Buy $13
Oct-10-12Resumed Canaccord Genuity Buy $8
May-26-11Initiated Canaccord Genuity Buy $6
Aug-26-15 07:00AM  AcelRx Pharmaceuticals to Participate at Three Investor Conferences In September PR Newswire
Aug-21-15 04:11PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements an
08:32AM  Why AceIRx (ACRX) Could Be a Potential Winner
Aug-11-15 01:05PM  ACELRX PHARMACEUTICALS INC Financials
Aug-06-15 08:09PM  10-Q for AcelRx Pharmaceuticals, Inc. at Company Spotlight -7.02%
08:51AM  Concert Pharmaceuticals (CNCE) in Focus: Stock Rises 5.2% - Tale of the Tape
Aug-04-15 04:32PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +9.88%
09:30AM  New Strong Buy Stocks for August 4th - Tale of the Tape
08:24AM  Edited Transcript of ACRX earnings conference call or presentation 3-Aug-15 8:30pm GMT
06:35AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
Aug-03-15 05:39PM  AcelRx Pharmaceuticals reports 2Q loss
04:30PM  AcelRx Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today
04:01PM  AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results PR Newswire
07:07AM  Q2 2015 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
Jul-29-15 05:05PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
07:00AM  AcelRx Pharmaceuticals to Hold Business Update and Second Quarter Financial Results Conference Call and Webcast on Monday, Aug. 3rd, 2015. PR Newswire
Jul-24-15 12:13PM  5 Stocks Poised for Breakouts at TheStreet
09:32AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
08:30AM  AcelRx Announces Positive CHMP Opinion for Zalviso in the Management of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients PR Newswire
Jul-14-15 02:21PM  3 Stocks Under $10 to Trade for Breakouts at TheStreet +6.31%
Jul-02-15 07:00AM  Zalviso Phase 3 Orthopedic Results Published In Anesthesiology Demonstrate Significant Reductions In Post-Operative Pain PR Newswire
Jul-01-15 12:02PM  10 Worst Biotech Stocks in the NASDAQ at TheStreet
Jun-26-15 05:07AM  Edited Transcript of ACRX presentation 1-Jun-15 8:00pm GMT
Jun-24-15 04:39PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
Jun-03-15 08:45AM  Can the Rally in AcelRx Pharmaceuticals (ACRX) Shares Continue? - Tale of the Tape +13.08%
May-22-15 07:00AM  AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June PR Newswire
May-19-15 02:16PM  7 Biotech Stocks Moving Off The UBS Healthcare Conference +10.19%
May-15-15 09:52AM  AcelRx Pharmaceuticals (ACRX) Looks Good: Stock Up 8% - Tale of the Tape
May-14-15 12:00PM  AcelRX Takes Flight With New Department of Defense Contract at 24/7 Wall St. +7.97%
07:00AM  AcelRx Awarded Contract from Department of Defense to Advance ARX-04 PR Newswire
06:08AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
May-08-15 04:50PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
May-07-15 08:09PM  10-Q for AcelRx Pharmaceuticals, Inc. at Company Spotlight
May-06-15 04:40PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
May-05-15 08:12PM  10-K for AcelRx Pharmaceuticals, Inc. at Company Spotlight -27.74%
04:50PM  The 52-Week Low Club for Tuesday at 24/7 Wall St.
04:37PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Ex
06:10AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report
May-04-15 06:18PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX Accesswire
06:04PM  AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results at noodls
04:56PM  5 Key After-Hours Movers on Monday at 24/7 Wall St.
04:46PM  FDA rejects AcelRx's request for meeting on pain drug device Reuters
04:43PM  AcelRx Pharmaceuticals reports 1Q loss
04:04PM  AcelRx Pharmaceuticals Provides Zalviso Regulatory Update and Reports First Quarter 2015 Financial Results PR Newswire
07:07AM  Q1 2015 AcelRx Pharmaceuticals Inc Earnings Release - After Market Close
May-01-15 07:54AM  AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May at noodls
07:00AM  AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May PR Newswire
Apr-30-15 07:12AM  AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 4th, 2015 at noodls -5.90%
07:00AM  AcelRx Pharmaceuticals to Hold First Quarter Financial Results Conference Call and Webcast on Monday, May 4th, 2015 PR Newswire
Apr-14-15 07:20AM  AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting at noodls
07:00AM  AcelRx Pharmaceuticals Announces Presentation Of Sublingual Sufentanil Data At The Society of American Gastrointestinal and Endoscopic Surgeons Meeting PR Newswire
Apr-08-15 06:26PM  AcelRx Pharmaceuticals, Inc. Former Employees With Information Concerning Zalviso System Dispensing Errors are Encouraged to Contact Brower Piven -- ACRX GlobeNewswire
Apr-03-15 05:31PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K/A, Entry into a Material Definitive Agreement, Change in Directors or P
Mar-23-15 12:15PM  AcelRx Pharmaceuticals: What Went Wrong and What's on the Horizon for the Struggling Biotech? at TheStreet
07:33AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Other Events
Mar-20-15 04:27PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities, Change in Directors
03:27PM  AcelRx Appoints Howard B. Rosen as Interim CEO at noodls
03:00PM  AcelRx Appoints Howard B. Rosen as Interim CEO PR Newswire
Mar-17-15 02:00PM  AcelRx Starts Pivotal Study on Acute Pain Management Drug - Analyst Blog
Mar-16-15 07:23AM  AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 at noodls
07:00AM  AcelRx Pharmaceuticals Announces Initiation Of Pivotal Phase 3 Trial For ARX-04 PR Newswire
Mar-14-15 09:20AM  8 Analyst Stocks Under $10 With Massive Upside Calls at 24/7 Wall St.
Mar-13-15 06:26PM  INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AcelRx Pharmaceuticals, Inc. (ACRX) To Contact The Firm PR Newswire
06:11AM  ACELRX PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Mar-10-15 12:21PM  AcelRx Pharmaceuticals (ACRX) Stock Extends Losses Today as Jefferies Downgrades at TheStreet -15.70%
11:55AM  Jefferies Downgrades AcelRx Pharmaceuticals After FDA Requests Additional Clinical Trial For Lead Drug Zalviso
08:55AM  Top Analyst Upgrades and Downgrades: AcelRx, AECOM, EA, HP, Myriad, Urban Outfitters and More at 24/7 Wall St.
Mar-09-15 10:10PM  AcelRx Pharma Meets Expectations, But Says It Won't Submit New Zalviso Application -36.96%
05:39PM  AcelRx Pharmaceuticals reports 4Q loss
04:14PM  AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results at noodls
04:05PM  AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results PR Newswire
03:40PM  EQUITY ALERT: The Rosen Law Firm Announces Investigation of Securities Claims Against AcelRx Pharmaceuticals, Inc. ACRX Business Wire
03:28PM  AcelRx Pharmaceuticals (ACRX) Stock Tanks Today on FDA Demand For Further Zalviso Trials at TheStreet
10:25AM  Can AcelRx Overcome Yet Another FDA Roadblock? at 24/7 Wall St.
10:24AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AcelRx Pharmaceuticals, Inc. - ACRX PR Newswire
08:53AM  AcelRx Says FDA Calls for Additional Trial on Zalviso at The Wall Street Journal
07:45AM  FDA asks AcelRx for additional trial on pain drug Reuters
07:30AM  AcelRx Provides Regulatory Update on Zalviso PR Newswire
Mar-06-15 08:46AM  Should You Sell AcelRx Pharmaceuticals (ACRX) Before Earnings? - Tale of the Tape Zacks
Mar-04-15 07:00AM  AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 PR Newswire
Feb-26-15 06:07AM  AcelRx upgraded by Mizuho Briefing.com
Feb-24-15 07:03AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-20-15 07:00AM  AcelRx Pharmaceuticals to Participate at Two Upcoming Investor Events PR Newswire
Feb-13-15 04:31PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Feb-09-15 06:07AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
Feb-04-15 07:00AM  AcelRx Pharmaceuticals to Present at BIO CEO & Investor Conference PR Newswire
Jan-15-15 09:59AM  Will the Second Time be a Charm for Biotech AcelRx After Their FDA Rejection? at TheStreet -6.09%
Jan-13-15 04:50PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosur EDGAR Online
Dec-16-14 05:05PM  AcelRx Pharmaceuticals Announces Departure of Richard A. King, President And CEO Benzinga
05:01PM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K/A, Change in Directors or Principal Officers, Financial Statements and EDGAR Online
Dec-15-14 06:26AM  La Jolla Pharmaceutical (LJPC) Jumps: Stock Gains 5.8% Zacks
Dec-08-14 06:06AM  ACELRX PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
05:58AM  Why AcelRx Pharmaceuticals (ACRX) Could Be Positioned for a Surge? Zacks
Dec-02-14 07:00AM  AcelRx Pharmaceuticals Receives CE Mark Approval for Zalviso PR Newswire
Nov-21-14 06:47PM  EQUITY ALERT: Rosen Law Firm P.A. Reminds AcelRx Pharmaceuticals, Inc. Investors of Important December 1, 2014 Class Action Deadline- ACRX GlobeNewswire
Nov-20-14 10:32AM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Lead Plaintiff Deadline In The Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. Business Wire
08:16AM  Zacks Rank #1 Additions for Thursday Zacks
07:00AM  AcelRx Pharmaceuticals to Participate in Four Upcoming Investor Events PR Newswire
Nov-19-14 09:42PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In AcelRx Pharmaceuticals, Inc. To Contact Brower Piven Before The December 1, 2014 Lead Plaintiff Deadline In Class Action Lawsuit Business Wire
Nov-17-14 06:48PM  UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Investors of Class Action Against AcelRx Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 1, 2014 Business Wire
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company's lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting. The company is also developing ARX-04, a sufentanil single-dose tablet, which has been planned to initiate Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as in the emergency room, hospital floor, ambulatory care facilities, or on the battlefield. In addition, its product candidate pipeline consists of ARX-02, a pain management system that has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a single, fixed-dose, and combination drug product, which has been completed Phase II clinical trial designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
EDWARDS MARK GDirectorMay 07Buy3.1340,000125,116100,000May 07 05:35 PM
Palmer Pamela PChief Medical OfficerMar 12Option Exercise1.3225,00033,000370,015Mar 17 03:58 PM